Patrizia Presbitero
A5069485910- Cardiac Valve Diseases and Treatments
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Issues in Pregnancy
- Congenital Heart Disease Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Aortic Disease and Treatment Approaches
- Cardiac Structural Anomalies and Repair
- Cerebrovascular and Carotid Artery Diseases
- Pulmonary Hypertension Research and Treatments
- Atrial Fibrillation Management and Outcomes
- Peripheral Artery Disease Management
- Cardiovascular Function and Risk Factors
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Cardiovascular and Diving-Related Complications
- Coronary Artery Anomalies
- Venous Thromboembolism Diagnosis and Management
- Vascular Procedures and Complications
- Health and Medical Research Impacts
- Lipoproteins and Cardiovascular Health
IRCCS Humanitas Research Hospital
2014-2025
Fondazione Humanitas per la Ricerca
2012-2022
Humanitas University
2010-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2021
Mount Sinai Hospital
2015-2018
Ospedale Cisanello
2018
McGill University Health Centre
2018
Institut Cardiovasculaire Paris Sud
2018
Icahn School of Medicine at Mount Sinai
2017
Società Italiana di Cardiologia Interventistica
2009-2017
Table 1. Classes of recommendation Table 2. Levels evidence Table 3. Estimated fetal and maternal effective doses for various diagnostic interventional radiology procedures Table 4. Predictors cardiovascular events risk score from the CARPREG study Table 5. identified in congential heart diseases ZAHARA Khairy 6. Modified WHO classification risk: principles Table 7. application Table 8. Maternal predictors neonatal women with disease Table 9. General recommendations Table 10....
Owing to a considerable shift toward bioprosthesis implantation rather than mechanical valves, it is expected that patients will increasingly present with degenerated bioprostheses in the next few years. Transcatheter aortic valve-in-valve less invasive approach for structural valve deterioration; however, comprehensive evaluation of survival after procedure has not yet been performed.To determine transcatheter inside failed surgical bioprosthetic valves.Correlates were evaluated using...
To assess the natural history, risk factors for death and deterioration of patients with Eisenmenger Syndrome.
In a series of 416 women with congenital heart disease seen in the Royal Brompton National Heart and Lung Hospital, London, Hospital Giovanni Bosco, Torino, Italy, there were 822 pregnancies. The outcomes 96 pregnancies 44 patients cyanotic studied. Patients Eisenmenger reaction excluded. divided arbitrarily into groups according to type maternal cardiac anomaly, factors influencing fetal outcome evaluated. incidence cardiovascular complications was high (32%), one death from endocarditis 2...
Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part percutaneous coronary intervention (PCI) in patients with an acute syndrome.We randomly assigned 7213 syndrome for whom PCI was anticipated to receive either or unfractionated heparin. Patients group were subsequently not a post-PCI infusion. Primary outcomes comparison between heparin occurrence major adverse cardiovascular events (a composite death, myocardial infarction, stroke) net clinical...
There are limited data on coronary obstruction following transcatheter valve-in-valve (ViV) implantation inside failed aortic bioprostheses. The objectives of this study were to determine the incidence, predictors, and clinical outcomes in ViV procedures. A total 1612 procedures from Valve-in-Valve International Data (VIVID) Registry evaluated. subject centralized blinded corelab computed tomography (CT) analysis a subset patients. virtual valve ostium distance (VTC) was determined. 37...
The late outcome in 226 patients who survived surgical repair of aortic coarctation was assessed 15-30 years after operation. Twenty six died during the follow up mainly from causes related to or associated cardiovascular anomalies. survival rates operated on between ages four and 20 are 97%, 92% at 10, 20, 30 For age corresponding 93%, 85%, 68%. This difference is statistically significant fifteenth year onwards. before not significantly different that a comparable general Italian...
Ventricular arrhythmias are common after repair of tetralogy Fallot and associated with late sudden death. This study examined the relation ventricular arrhythmia during normal daily activities to timing repair, duration follow up, postoperative haemodynamic status. Forty eight hour ambulatory electrocardiographic monitoring was performed in 145 patients: 60 (aged 3 months 46 years) had not yet undergone 85 were followed from four 22 (mean 14.6) years repair. Cardiac catheterisation 47 (55%)...
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There no data on long-term outcomes after ViV. Our aim was perform a large-scale assessment of survival and reintervention ViV.A total 1006 ViV performed more than 5 years ago [mean age 77.7 ± 9.7 years; 58.8% male; median STS-PROM score 7.3% (4.2-12.0)] were included in the analysis. Patients treated with Medtronic self-expandable valves (CoreValve/Evolut, Inc., Minneapolis, MN, USA)...
Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous repair or replacement. Our aim was perform a large-scale analysis examining midterm outcomes ViV ViR.Patients undergoing ViR were enrolled the Valve-in-Valve International Data Registry. Cases performed between March 2006 2020. Clinical endpoints reported according Valve Academic Research Consortium (MVARC) definitions. Significant...
We sought to evaluate the outcome of transcatheter aortic valve replacement (TAVR) with CoreValve Revalving System (CRS-TAVR) in inoperable patients presenting severe regurgitation (AR), compared treated for native stenosis (AS). From October 2008 January 2013, 1,557 consecutive undergoing CRS-TAVR, whom 26 (1.6%) presented AR, were prospectively followed. Compared AS, AR significantly younger (mean age 73±10 vs. 82±6, p=0.02), more frequently NYHA Class III/IV (95% 73%, p=0.01) and had a...